Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Tirumotecan Plus Pembrolizumab in Advanced Biliary Tract Cancer
NCT07850791Phase 2Recruiting
- Sponsor
- Purinomia Biotech
- Start
- Oct 2026
- Primary completion
- Oct 2028
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab tirumotecan in biliary tract cancer (BTC), sponsored by Purinomia Biotech. Primary endpoint: Objective Response Rate at 12 months. Started Oct 2026; status: recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT07850791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07850791.